| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 70 |
| 1 | PEMBROLIZUMAB | 68 |
| 2 | PACLITAXEL | 65 |
| 3 | PACLITAXEL (AIBUMIN-BOUND) | 63 |
| 4 | CARBOPLATIN | 52 |
| 5 | CISPLATIN | 36 |
| 6 | LENVATINIB | 20 |
| 7 | FOLIC ACID | 15 |
| 8 | IBUPROFEN | 14 |
| 9 | HYDROCORTISONE | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ESTRIOL | 4 | 0.0022 |
| 1 | KETAMINE HYDROCHLORIDE | 5 | 0.0010 |
| 2 | PROPYLTHIOURACIL | 2 | 0.0010 |
| 3 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 4 | DOSTARLIMAB | 2 | 0.0008 |
| 5 | PACLITAXEL | 65 | 0.0006 |
| 6 | PEMBROLIZUMAB | 68 | 0.0006 |
| 7 | NALDEMEDINE | 1 | 0.0006 |
| 8 | LENVATINIB | 20 | 0.0006 |
| 9 | BEVACIZUMAB | 70 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 87 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 72 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 70 |
| 3 | Microtubule Inhibitor [EPC] | 67 |
| 4 | Corticosteroid [EPC] | 25 |
| 5 | Kinase Inhibitor [EPC] | 25 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 22 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 17 |
| 8 | Vitamin B12 [EPC] | 16 |
| 9 | Vitamin C [EPC] | 16 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 72 | 0.0007 |
| 1 | Semifluorinated Alkane [EPC] | 1 | 0.0004 |
| 2 | Microtubule Inhibitor [EPC] | 67 | 0.0004 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 70 | 0.0004 |
| 4 | Platinum-based Drug [EPC] | 87 | 0.0003 |
| 5 | Nitrofuran Antibacterial [EPC] | 4 | 0.0002 |
| 6 | Thyroid Hormone Synthesis Inhibitor [EPC] | 2 | 0.0002 |
| 7 | Catechol-O-Methyltransferase Inhibitor [EPC] | 1 | 0.0002 |
| 8 | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] | 1 | 0.0001 |
| 9 | Cephalosporin Antibacterial [EPC] | 1 | 0.0001 |